CMX001. Anti-smallpox agent, anti-cytomegalovirus agent, viral polymerase inhibitor

Drugs of the Future

Volumn 33, Issue 8, 2008, Pages 655-661

  Painter, George R ^a   Trost, Lawrence C ^a   Lampert, Bernhard M ^a   Almond, Merrick R ^a   Buller, Mark ^b   Kern, Earl ^c   Painter, Gwendolyn P ^a   Robertson, Alice T ^a   Frazer, Neil ^a   O'Mahony, Rosemary ^a  

^a Chimerix Inc   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O HEXADECYLOXYPROPYLCIDOFOVIR; ANTIVIRUS AGENT; CIDOFOVIR; CMX 001; CMX 021; CMX 064; GANCICLOVIR; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DNA VIRUS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INFECTION PREVENTION; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NEPHROTOXICITY; NONHUMAN; RETINITIS; SINGLE DRUG DOSE; SMALLPOX; VACCINATION;

EID: 59349108443     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.08.1233987     Document Type: Article

References (29)

1. Kern, E.R., Hartline, C., Harden, E., Keith, K., Rodriquez, N., Beadle, J.R., Hostetler, K.Y. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrob Agents Chemother 2002, 46(4): 991-5.
2. Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., Ladny, I.D. Smallpox and its eradication. World Health Organization, Geneva, 1988.
3. Parker, S., Nuara, A., Buller, R.M., Schultz, D.A. Human monkeypox: An emerging zoonotic disease. Future Microbiol 2007, 2: 17-34.
4. Emerg, V.C. Investigation of CMV disease in immunocompromised patients. J Clin Pathol 2001, 54(2): 84-8.
5. Fishman, J.A., Emery, V., Freeman, R. et al. Cytomegalovirus in transplantation challenging the status quo. Clin Transplant 2007, 21(2): 149-58.
6. Singh, N. Interactions between viruses in transplant recipients. Clin Infect Dis 2005, 40(3): 430-6.
7. De Clerq, E. Clinical potential of the acyclic nucleosides phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003, 16(4): 569-96.
8. Painter, G.R., Hostetler, K.Y. Design and development of oral drugs for the prophylaxis and treatment of smallpox infection. Trends Biotechnol 2004, 22(8): 423-7.
9. Hartline, C.B., Gustin, K.M., Wan, W.B., Ciesla, S.L., Beadle, J.R., Hostetler, K.Y., Kern, E.R. Ether lipid ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro. J Infect Dis 2005, 191(3): 396-9.
10. Hostetler, K.Y., Rought, S., Aldern, K.A., Trahan, J., Beadle, J.R., Corbeil, J. Enhanced antioroliferative effects of alkoxyalkyl esters of cidohovir in human cervical cancer cells in vitro. Mol Cancer Ther 2006, 5(1): 156-9.
11. Randhawa, P., Farasati, N.A., Shapiro, R., Hostetler, K.Y. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chernother 2006, 50(4): 1564-6.
12. Huggins, J.W., Baker, J.R., Hostetler, K.Y. Orally active ether lipid prodrugs of cidohovir for the treatment of smallpox. Antivir Res 2002, 53(3): Abst A66.
13. Buller, R.M., Owens, G., Schriewer, J., Melman, L., Beadle, J. R., Hostetler, K. Y. Efficacy of orally active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318(2): 474-81.
14. Smee, D.F., Sidwell, R.W., Kefauver, D., Bray, M., Huggins, J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox and vaccinia viruses. Antimicrob Agents Chemother 2002, 46(5): 1329-35.
15. Adrei, G., Holy, A., Fiter, P., Opdenakker, G., De Clercq, E., Snoeck, R. Isolation of vaccinia virus (VV) mutants resistant to different acyclic nucleoside phosphonate analogues. Antivir Res 2004, 62(2): Abst A72.
16. Smee, D.F., Bailey, K.W., Holy, A., Sidwell, R.W. A cidofovir-resistant form of the highly virulent WR strain of vaccinia virus is cross-resistant to related antiviral agents and is highly attenuated for virulence in mice. Antivir Res 2004, 62(2): Abst A57.
17. Quenelle, D.C., Collins, D.J., Wan, W.B., Beadle, J.R., Hostetler, K.Y., Kern, E.R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004, 48(2): 404-12.
18. Parker, S., Touchette, E., Oberle, C. et al. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antivir Res 2007, 77(1): 39-49.
19. Adams, M.M., Rice, A.D., Moyer, R.W. Rabbitpox and vaccinia virus infection of rabbits as a model for human smallpox. J Virol 2007, 81(20): 11084-95.
20. Beadle, J.R., Hartline, C., Aldern, K.A., Rodriquez, N., Harden, E., Kern, E. R., Hostetler, K.Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002, 46(8): 2381-6.
21. Smith, I.L., Cherrington, J.M., Jiles, R.E., Fuller, M.D., Freeman, W.R., Spector, S.A. High level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the Nh97 and DNA polymerase genes. J Infect Dis 1997, 176(1): 69-79.
22. Bidanset, D.J., Beadle, J.R., Wan, W.B., Hostetler, K.Y., Kern, E.R. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infections. J Infect Dis 2004, 190(3): 499-503.
23. Bidanset, D.J., Rybak, R.J., Hartline, C.B., Kern, E.R. Replication of human cytomegalovirus in severe combined immunodeficient mice implanted with human retinal tissue. J Infect Dis 2001, 184(2): 192-5.
24. 14C] cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol 2003, 63(3): 578-81.
25. Cihlar, T., Chen, M.S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol 1996, 50(6): 1502-10.
26. Xiong, X., Smith, J.L., Kim, C., Huang, E,-S., Ming, S.C. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol 1996, 51(11): 1563-7.
27. Xiong, X., Smith, J.L., Chien, M.S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997, 41(3): 594-9.
28. Magee, E.C., Hostetler, K.Y., Evans, D.H. Mechanism of inhihition of vaccinia virus DNA polymerase by cidofovir diphospoate. Antimircrob Agents Chemother 2005, 49(8): 3153-62.
29. Cherrington, J.M., Allen, S.J., McKee, B.H., Chen, M.S. Kinetic analysis of interaction between the diphosphate of (S)-1- (3-hydroxy-2-phosphonyl-methoxypropyl) cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerase β and γ. Biochem Pharmacol 1994, 48(10): 1986-98.